Table 1:
Characteristics of women with each endpoint of interest and overall.
| Moderate dysplasia | Severe dysplasia | Carcinoma in situ | Cervical Cancer | Overall* | |
|---|---|---|---|---|---|
|
| |||||
| N | 3556 | 3417 | 700 | 564 | 517312 |
| Women with HIV (%) | 1105 (31.1) | 1042 (30.5) | 206 (29.4) | 132 (23.4) | 38739 (7.5) |
| Age group** (%) | |||||
| 18–24 | 377 (10.6) | 264 (7.7) | 57 (8.1) | 5 (0.9) | 95361 (18.4) |
| 25–34 | 1665 (46.8) | 1462 (42.8) | 245 (35.0) | 64 (11.3) | 139078 (26.9) |
| 35–44 | 1045 (29.4) | 1091 (31.9) | 228 (32.6) | 147 (26.1) | 105979 (20.5) |
| 45–54 | 358 (10.1) | 464 (13.6) | 113 (16.1) | 177 (31.4) | 84585 (16.4) |
| 55–64 | 93 (2.6) | 119 (3.5) | 39 (5.6) | 103 (18.3) | 52576 (10.2) |
| ≥65 | 18 (0.5) | 17 (0.5) | 18 (2.6) | 68 (12.1) | 39733 (7.7) |
| Calendar year** (%) | |||||
| 2011–2013 | 2371 (66.7) | 2339 (68.5) | 494 (70.6) | 400 (70.9) | 276235 (53.4) |
| 2014–2016 | 728 (20.5) | 657 (19.2) | 118 (16.9) | 66 (11.7) | 86771 (16.8) |
| 2017–2020 | 457 (12.9) | 421 (12.3) | 88 (12.6) | 98 (17.4) | 154306 (29.8) |
| History of genital warts*** (%) | 182 (5.1) | 137 (4.0) | 36 (5.1) | 10 (1.8) | 2936 (0.6) |
| History of other STIs*** (%) | 165 (4.6) | 142 (4.2) | 35 (5.0) | 23 (4.1) | 10736 (2.1) |
| History of oral contraceptive use***(%) | 334 (9.4) | 266 (7.8) | 51 (7.3) | 12 (2.1) | 49425 (9.6) |
*
Individuals in analysis of cervical cancer (numbers for the analyses of the other endpoints vary slightly)
**
Baseline=last from: enrolment date, date person turns 18, January 1st 2011, or date of first HIV indicator
***
During or before follow-up